|Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia|
GA Calin, CD Dumitru, M Shimizu, R Bichi, S Zupo, E Noch, H Aldler, ...
Proceedings of the national academy of sciences 99 (24), 15524-15529, 2002
|miR-15 and miR-16 induce apoptosis by targeting BCL2|
A Cimmino, GA Calin, M Fabbri, MV Iorio, M Ferracin, M Shimizu, ...
Proceedings of the National Academy of Sciences 102 (39), 13944-13949, 2005
|Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National …|
M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ...
Blood, The Journal of the American Society of Hematology 111 (12), 5446-5456, 2008
|A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia|
GA Calin, M Ferracin, A Cimmino, G Di Leva, M Shimizu, SE Wojcik, ...
New England Journal of Medicine 353 (17), 1793-1801, 2005
|MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias|
GA Calin, CG Liu, C Sevignani, M Ferracin, N Felli, CD Dumitru, ...
Proceedings of the National Academy of Sciences 101 (32), 11755-11760, 2004
|Idelalisib and rituximab in relapsed chronic lymphocytic leukemia|
RR Furman, JP Sharman, SE Coutre, BD Cheson, JM Pagel, P Hillmen, ...
New England Journal of Medicine 370 (11), 997-1007, 2014
|Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia|
A Rosenwald, AA Alizadeh, G Widhopf, R Simon, RE Davis, X Yu, L Yang, ...
The Journal of experimental medicine 194 (11), 1639-1648, 2001
|CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment|
JA Burger, TJ Kipps
Blood 107 (5), 1761-1767, 2006
|Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia|
JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ...
New England Journal of Medicine 371 (3), 213-223, 2014
|ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia|
LZ Rassenti, L Huynh, TL Toy, L Chen, MJ Keating, JG Gribben, ...
New England Journal of Medicine 351 (9), 893-901, 2004
|Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia|
AW Roberts, MS Davids, JM Pagel, BS Kahl, SD Puvvada, JF Gerecitano, ...
New England Journal of Medicine 374 (4), 311-322, 2016
|Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.|
F Fais, F Ghiotto, S Hashimoto, B Sellars, A Valetto, SL Allen, P Schulman, ...
The Journal of clinical investigation 102 (8), 1515-1525, 1998
|Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia|
JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ...
New England Journal of Medicine 373 (25), 2425-2437, 2015
|MiR-15a and miR-16-1 cluster functions in human leukemia|
GA Calin, A Cimmino, M Fabbri, M Ferracin, SE Wojcik, M Shimizu, ...
Proceedings of the National Academy of Sciences 105 (13), 5166-5171, 2008
|Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell–derived factor-1|
JA Burger, N Tsukada, M Burger, NJ Zvaifler, M Dell'Aquila, TJ Kipps
Blood, The Journal of the American Society of Hematology 96 (8), 2655-2663, 2000
|Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181|
Y Pekarsky, U Santanam, A Cimmino, A Palamarchuk, A Efanov, ...
Cancer research 66 (24), 11590-11593, 2006
|Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas|
GA Calin, C Liu, M Ferracin, T Hyslop, R Spizzo, C Sevignani, M Fabbri, ...
Cancer cell 12 (3), 215-229, 2007
|Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal.|
EA Ranheim, TJ Kipps
The Journal of experimental medicine 177 (4), 925-935, 1993
|Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease|
AW Roberts, JF Seymour, JR Brown, WG Wierda, TJ Kipps, SL Khaw, ...
Journal of Clinical Oncology 30 (5), 488, 2012
|Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia|
WG Wierda, TJ Kipps, J Mayer, S Stilgenbauer, CD Williams, A Hellmann, ...
Journal of Clinical Oncology 28 (10), 1749, 2010